Genentech (Seagul) – Lucentis for AMD

Who is the sponsor?

Who are the patients?
Male or female over the age of fifty years with AMD The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long are the eligible patients enrollment?
Assessments for treatment will be done monthly for a period of 12 months.

When did participation agreement start at our site?
August 2007

What is the enrollment goal for the sponsor?
Twenty patients.

Is the enrollment still open?
No. This study is now closed.

What is this study investigating?
This is an open-label study of treatment-naive patients treated with on-label ranibizumab for neovascular age-related macular degeneration (AMD) with the following objective: To determine VEGF and HTRA1 SNP genotypes of patients gaining ?0 letters of visual acuity in response to ranibizumab treatment over a 4 month period. To determine VEGF and HTRA1 SNP genotypes of patients with worse3ning vision (gaining <0 letters) while receiving ranibizumab treatment over 4 and 12 month periods, as well as patients gaining ?0 letters over 6 and 12 month time periods. Lastly, to correlate changes in retinal thickness in patients receiving Lucentis with their genotypes.

How is the treatment administered?
Intravitreal Injections of LucentisTM (ranibizumab)